Navigation Links
BioMarin to Present at the UBS Global Life Sciences Conference
Date:9/14/2010

NOVATO, Calif., Sept. 14 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President, Corporate and Business Development of BioMarin, will present a company update at the UBS Global Life Sciences Conference in New York City on Tuesday, September 21, 2010 at 3:30 p.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Eugenia ShenBioMarin Pharmaceutical Inc.(415) 506-6570
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
2. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
3. BioMarin Acquires ZyStor Therapeutics, Inc.
4. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
5. BioMarin to Acquire LEAD Therapeutics
6. BioMarin to Present at the Credit Suisse Healthcare Conference
7. BioMarin Announces Third Quarter 2009 Financial Results
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Acquires Huxley Pharmaceuticals, Inc.
10. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
11. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
Breaking Medicine Technology:
(Date:9/21/2017)... Va. (PRWEB) , ... September 21, 2017 , ... ... with a different approach to addiction recovery at a time when Virginia faces ... deaths resulting from drug overdose, a staggering increase of 38 percent from 2015, ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... the acquisition of Isle at Kingwood Assisted Living and Memory Care located at ... retirement community with 55 assisted living apartments, 43 memory care apartments and 23 ...
(Date:9/21/2017)... ... September 21, 2017 , ... In ... and Clark College Emeritus Professor of Education Gregory A. Smith examines student privacy ... Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure of Policymaking . ...
(Date:9/20/2017)... CHARLOTTE, NC (PRWEB) , ... September 20, 2017 ... ... for Transformation and Centers of Excellence (CoE) with the latest Artificial Intelligence (AI) ... newly designed presence offers quick and easy access to essential information that offers ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... one of the Best Places to Work in the Research Triangle for 2017. ... Once nominated, a company had to meet a threshold in employee participation--a percentage ...
Breaking Medicine News(10 mins):